D-Lin-MC3-DMA | CAS#1224606-06-7 | cationic lipid

MedKoo Cat#: 555308 | Name: D-Lin-MC3-DMA

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DLin-MC3-DMA, or D-Lin-MC3-DMA, is the most potent cationic lipid that has been synthesized for lipid nanoparticles (LNPs) to deliver the siRNA. D-Lin-MC3-DMA is useful for design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. LNP systems containing D-Lin-MC3-DMA can be highly effective, non-toxic pDNA delivery systems for gene expression both in vitro and in vivo.

Chemical Structure

D-Lin-MC3-DMA

CAS#1224606-06-7

Theoretical Analysis

MedKoo Cat#: 555308

Name: D-Lin-MC3-DMA

CAS#: 1224606-06-7

Chemical Formula: C43H79NO2

Exact Mass: 641.6111

Molecular Weight: 642.11

Elemental Analysis: C, 80.43; H, 12.40; N, 2.18; O, 4.98

Price and Availability

Size	Price	Availability
10mg	USD 135.00	Ready to ship
25mg	USD 225.00	Ready to ship
50mg	USD 405.00	Ready to ship
100mg	USD 765.00	Ready to ship
200mg	USD 1,120.00	Ready to ship
500mg	USD 2,450.00	Ready to ship
1g	USD 4,150.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1258299-72-7 (deleted) 1224606-06-7

Synonym

D-Lin-MC3-DMA; DLin-MC3-DMA; Dlin-mc3-dma; MC 3; MC3; MC-3; RV 28; RV-28; RV28;

IUPAC/Chemical Name

(6Z,9Z,28Z,31Z)-Heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate

InChi Key

NRLNQCOGCKAESA-KWXKLSQISA-N

InChi Code

InChI=1S/C43H79NO2/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-38-42(46-43(45)40-37-41-44(3)4)39-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h13-16,19-22,42H,5-12,17-18,23-41H2,1-4H3/b15-13-,16-14-,21-19-,22-20-

SMILES Code

O=C(OC(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCCCC/C=C\C/C=C\CCCCC)CCCN(C)C

Appearance

Colorless to light yellow liquid

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO (40mg/ mL) and soluble in ethanol (15mg/mL).

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#YXM210629

View CoA: current batch, Lot#YXM90829

QC Data

View QC data: current batch, Lot#YXM90829

View QC data: current batch, Lot#YXM210629

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

siRNA delivery vehicle

In vitro activity:

From the data in Fig. 5 A and D, the DLin-MC3-DMA/Chol system, in the absence of RNA, clearly forms a regular inverse hexagonal H2 phase at the LNP preparation conditions, pH 3 with 25% ethanol. At this condition, DLin-MC3-DMA is expected to be fully ionized (apparent pKa 6.44) (23). The addition of RNA to the LNPs, in pH 3 and 25% ethanol, decreases the order because the second-order peaks become less pronounced. This can be understood as follows: RNA (with its counterions), located inside the aqueous cylinders, screens the charges of the DLin-MC3-DMA, thereby making cylinders more flexible, i.e., decreasing their persistence length. At neutral conditions (PBS, pH 7.4, data in Fig. 5 B and E), DLin-MC3-DMA will be less ionized, and the nonionic fraction (expected to be significant at this pH) will to some extent act as a solvent, leading to a further decrease of the order in the system. In fact, this phase, when observed by polarized microscopy, is isotropic, which is also consistent with the almost perfect spherical shape of the LNPs (Fig. 2). Reference: Proc Natl Acad Sci U S A. 2018 Apr 10; 115(15): E3351–E3360. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899464/

In vivo activity:

Healthy NSG mice were injected with a therapeutic dose of 5mg/kg LNP-CTRL siRNA (LNP: lipid nanoparticle) at regular time intervals (see Figure 5A for injection schedule). CTRL or AHA1 is a targeting functional siRNA used as control, as knockdown of AHA1 has no reported phenotype. To first evaluate the uptake efficiency, injected mice were bled at regular time intervals and analyzed for the percentage and fluorescence intensity of DiI positive cells in the PB. We found that a total dose of 10 mg/kg LNP-CTRL siRNA (2 injections) resulted in a 100% uptake in peripheral blood cells, but a total dose of 15 mg/kg (3 injections over 24 hours) resulted in higher fluorescence intensity (Figure 5B and 5C, respectively). Interestingly, LNP-siRNA uptake was very stable in vivo as almost 100% peripheral blood cells were positive until day 10 after administration of the first 3 doses (Figure 5B). Peak fluorescence intensity was maintained through day 4, while DiI fluorescence intensity decreased over time (Figure 5C). Reference: Ann Hematol. 2019 Aug 1; 98(8): 1905–1918. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116733/

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	155.74
	Ethanol	50.0	77.87

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 642.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Yanez Arteta M, Kjellman T, Bartesaghi S, Wallin S, Wu X, Kvist AJ, Dabkowska A, Székely N, Radulescu A, Bergenholtz J, Lindfors L. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3351-E3360. doi: 10.1073/pnas.1720542115. Epub 2018 Mar 27. PMID: 29588418; PMCID: PMC5899464. 2. Jyotsana N, Sharma A, Chaturvedi A, Budida R, Scherr M, Kuchenbauer F, Lindner R, Noyan F, Sühs KW, Stangel M, Grote-Koska D, Brand K, Vornlocher HP, Eder M, Thol F, Ganser A, Humphries RK, Ramsay E, Cullis P, Heuser M. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo. Ann Hematol. 2019 Aug;98(8):1905-1918. doi: 10.1007/s00277-019-03713-y. Epub 2019 May 18. PMID: 31104089; PMCID: PMC7116733.

In vitro protocol:

In vivo protocol:

1. Jyotsana N, Sharma A, Chaturvedi A, Budida R, Scherr M, Kuchenbauer F, Lindner R, Noyan F, Sühs KW, Stangel M, Grote-Koska D, Brand K, Vornlocher HP, Eder M, Thol F, Ganser A, Humphries RK, Ramsay E, Cullis P, Heuser M. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo. Ann Hematol. 2019 Aug;98(8):1905-1918. doi: 10.1007/s00277-019-03713-y. Epub 2019 May 18. PMID: 31104089; PMCID: PMC7116733.

1: Ferraresso F, Strilchuk AW, Juang LJ, Poole LG, Luyendyk JP, Kastrup CJ. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells. Mol Pharm. 2022 Jul 4;19(7):2175-2182. doi: 10.1021/acs.molpharmaceut.2c00033. Epub 2022 May 31. PMID: 35642083; PMCID: PMC9621687. 2: Ermilova I , Swenson J . DOPC versus DOPE as a helper lipid for gene- therapies: molecular dynamics simulations with DLin-MC3-DMA. Phys Chem Chem Phys. 2020 Dec 23;22(48):28256-28268. doi: 10.1039/d0cp05111j. PMID: 33295352. 3: Ibrahim M, Gilbert J, Heinz M, Nylander T, Schwierz N. Structural insights on ionizable Dlin-MC3-DMA lipids in DOPC layers by combining accurate atomistic force fields, molecular dynamics simulations and neutron reflectivity. Nanoscale. 2023 Jul 13;15(27):11647-11656. doi: 10.1039/d3nr00987d. PMID: 37377412. 4: Algarni A, Pilkington EH, Suys EJA, Al-Wassiti H, Pouton CW, Truong NP. In vivo delivery of plasmid DNA by lipid nanoparticles: the influence of ionizable cationic lipids on organ-selective gene expression. Biomater Sci. 2022 May 31;10(11):2940-2952. doi: 10.1039/d2bm00168c. PMID: 35475455. 5: Zimmermann CM, Baldassi D, Chan K, Adams NBP, Neumann A, Porras-Gonzalez DL, Wei X, Kneidinger N, Stoleriu MG, Burgstaller G, Witzigmann D, Luciani P, Merkel OM. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery. J Control Release. 2022 Nov;351:137-150. doi: 10.1016/j.jconrel.2022.09.021. Epub 2022 Sep 22. PMID: 36126785; PMCID: PMC7613708. 6: Kulkarni JA, Myhre JL, Chen S, Tam YYC, Danescu A, Richman JM, Cullis PR. Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. Nanomedicine. 2017 May;13(4):1377-1387. doi: 10.1016/j.nano.2016.12.014. Epub 2016 Dec 28. PMID: 28038954. 7: Henderson MI, Eygeris Y, Jozic A, Herrera M, Sahay G. Leveraging Biological Buffers for Efficient Messenger RNA Delivery via Lipid Nanoparticles. Mol Pharm. 2022 Nov 7;19(11):4275-4285. doi: 10.1021/acs.molpharmaceut.2c00587. Epub 2022 Sep 21. PMID: 36129254; PMCID: PMC9916253. 8: Riley RS, Kashyap MV, Billingsley MM, White B, Alameh MG, Bose SK, Zoltick PW, Li H, Zhang R, Cheng AY, Weissman D, Peranteau WH, Mitchell MJ. Ionizable lipid nanoparticles for in utero mRNA delivery. Sci Adv. 2021 Jan 13;7(3):eaba1028. doi: 10.1126/sciadv.aba1028. PMID: 33523869; PMCID: PMC7806221. 9: Miao L, Lin J, Huang Y, Li L, Delcassian D, Ge Y, Shi Y, Anderson DG. Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver. Nat Commun. 2020 May 15;11(1):2424. doi: 10.1038/s41467-020-16248-y. PMID: 32415122; PMCID: PMC7229004. 10: M Bailey-Hytholt C, Ulinski G, Dugas J, Haines M, Lazebnik M, Piepenhagen P, E Zarraga I, Bandekar A. Intracellular trafficking kinetics of nucleic acid escape from lipid nanoparticles via fluorescence imaging. Curr Pharm Biotechnol. 2023 Apr 3. doi: 10.2174/1389201024666230403094238. Epub ahead of print. PMID: 37016519. 11: Yanez Arteta M, Kjellman T, Bartesaghi S, Wallin S, Wu X, Kvist AJ, Dabkowska A, Székely N, Radulescu A, Bergenholtz J, Lindfors L. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3351-E3360. doi: 10.1073/pnas.1720542115. Epub 2018 Mar 27. PMID: 29588418; PMCID: PMC5899464. 12: Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis. J Clin Pharmacol. 2020 Jan;60(1):37-49. doi: 10.1002/jcph.1480. Epub 2019 Jul 19. PMID: 31322739; PMCID: PMC6972979. 13: Biscans A, Ly S, McHugh N, Cooper DA, Khvorova A. Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo. J Control Release. 2022 Sep;349:831-843. doi: 10.1016/j.jconrel.2022.07.041. Epub 2022 Aug 3. PMID: 35917865; PMCID: PMC10281028. 14: Ermilova I, Swenson J. Ionizable lipids penetrate phospholipid bilayers with high phase transition temperatures: perspectives from free energy calculations. Chem Phys Lipids. 2023 Jul;253:105294. doi: 10.1016/j.chemphyslip.2023.105294. Epub 2023 Mar 31. PMID: 37003484. 15: Philipp J, Dabkowska A, Reiser A, Frank K, Krzysztoń R, Brummer C, Nickel B, Blanchet CE, Sudarsan A, Ibrahim M, Johansson S, Skantze P, Skantze U, Östman S, Johansson M, Henderson N, Elvevold K, Smedsrød B, Schwierz N, Lindfors L, Rädler JO. pH-dependent structural transitions in cationic ionizable lipid mesophases are critical for lipid nanoparticle function. Proc Natl Acad Sci U S A. 2023 Dec 12;120(50):e2310491120. doi: 10.1073/pnas.2310491120. Epub 2023 Dec 6. PMID: 38055742; PMCID: PMC10723131. 16: Tesei G, Hsiao YW, Dabkowska A, Grönberg G, Yanez Arteta M, Ulkoski D, Bray DJ, Trulsson M, Ulander J, Lund M, Lindfors L. Lipid shape and packing are key for optimal design of pH-sensitive mRNA lipid nanoparticles. Proc Natl Acad Sci U S A. 2024 Jan 9;121(2):e2311700120. doi: 10.1073/pnas.2311700120. Epub 2024 Jan 4. PMID: 38175863; PMCID: PMC10786277. 17: Lam K, Leung A, Martin A, Wood M, Schreiner P, Palmer L, Daly O, Zhao W, McClintock K, Heyes J. Unsaturated, Trialkyl Ionizable Lipids are Versatile Lipid-Nanoparticle Components for Therapeutic and Vaccine Applications. Adv Mater. 2023 Apr;35(15):e2209624. doi: 10.1002/adma.202209624. Epub 2023 Mar 5. PMID: 36680477. 18: Chen Z, Tian Y, Yang J, Wu F, Liu S, Cao W, Xu W, Hu T, Siegwart DJ, Xiong H. Modular Design of Biodegradable Ionizable Lipids for Improved mRNA Delivery and Precise Cancer Metastasis Delineation In Vivo. J Am Chem Soc. 2023 Nov 8;145(44):24302-24314. doi: 10.1021/jacs.3c09143. Epub 2023 Oct 19. PMID: 37853662. 19: Badri P, Habtemariam B, Melch M, Clausen VA, Arum S, Li X, Jay PY, Vest J, Robbie GJ. Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation. Clin Pharmacokinet. 2023 Oct;62(10):1509-1522. doi: 10.1007/s40262-023-01292-w. Epub 2023 Aug 28. PMID: 37639169. 20: Nakamura T, Nakade T, Sato Y, Harashima H. Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles. Int J Pharm. 2023 Apr 5;636:122810. doi: 10.1016/j.ijpharm.2023.122810. Epub 2023 Mar 8. PMID: 36898618.

1. Liu S, Cheng Q, Wei T, Yu X, Johnson LT, Farbiak L, Siegwart DJ. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing. Nat Mater. 2021 May;20(5):701-710. doi: 10.1038/s41563-020-00886-0. Epub 2021 Feb 4. PMID: 33542471; PMCID: PMC8188687.

2. Lokugamage MP, Vanover D, Beyersdorf J, Hatit MZC, Rotolo L, Echeverri ES, Peck HE, Ni H, Yoon JK, Kim Y, Santangelo PJ, Dahlman JE. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat Biomed Eng. 2021 Sep;5(9):1059-1068. doi: 10.1038/s41551-021-00786-x. Epub 2021 Oct 6. PMID: 34616046.

3. Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020 Apr;15(4):313-320. doi: 10.1038/s41565-020-0669-6. Epub 2020 Apr 6. PMID: 32251383; PMCID: PMC7735425.

4. Wei T, Cheng Q, Min YL, Olson EN, Siegwart DJ. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun. 2020 Jun 26;11(1):3232. doi: 10.1038/s41467-020-17029-3. PMID: 32591530; PMCID: PMC7320157.

5. Jackson MA, Patel SS, Yu F, Cottam MA, Glass EB, Hoogenboezem EN, Fletcher RB, Dollinger BR, Patil P, Liu DD, Kelly IB, Bedingfield SK, King AR, Miles RE, Hasty AM, Giorgio TD, Duvall CL. Kupffer cell release of platelet activating factor drives dose limiting toxicities of nucleic acid nanocarriers. Biomaterials. 2021 Jan;268:120528. doi: 10.1016/j.biomaterials.2020.120528. Epub 2020 Nov 23. PMID: 33285438; PMCID: PMC7856291.

6. Fang-Yi Su, Qingyang Zhao, Shreyas N. Dahotre, Lena Gamboa, Swapnil Subhash Bawage, Aaron D. Silva Trenkle, Ali Zamat, Hathaichanok Phuengkham, Rafi Ahmed, Philip J. Santangelo, Gabriel A. Kwong In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles. doi: https://doi.org/10.1101/2021.10.14.464373. Als see web page: https://www.biorxiv.org/content/10.1101/2021.10.14.464373v1.abstract

7. Zhao, Weiyu. Development of Functionalized Biomaterials for Biomedical Applications. Dissertation document_Weiyu Zhao.pdf (2.59 MB. 2020, Doctor of Philosophy, Ohio State University, Pharmacy. https://etd.ohiolink.edu/apexprod/rws_olink/r/1501/10?clear=10&p10_accession_num=osu1594988786199951

8. Su FY, Zhao QH, Dahotre SN, Gamboa L, Bawage SS, Silva Trenkle AD, Zamat A, Phuengkham H, Ahmed R, Santangelo PJ, Kwong GA. In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles. Sci Adv. 2022 Feb 25;8(8):eabm7950. doi: 10.1126/sciadv.abm7950. Epub 2022 Feb 23. PMID: 35196075; PMCID: PMC8865765.

9. Cui Z, Zeng C, Huang F, Yuan F, Yan J, Zhao Y, Zhou Y, Hankey W, Jin VX, Huang J, Staats HF, Everitt JI, Sempowski GD, Wang H, Dong Y, Liu SL, Wang Q. Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection. Nat Chem Biol. 2022 Jul 25. doi: 10.1038/s41589-022-01094-4. Epub ahead of print. PMID: 35879545.

10. Zhu Y, Shen R, Vuong I, Reynolds RA, Shears MJ, Yao ZC, Hu Y, Cho WJ, Kong J, Reddy SK, Murphy SC, Mao HQ. Multi-step screening of DNA/lipid nanoparticles and co-delivery with siRNA to enhance and prolong gene expression. Nat Commun. 2022 Jul 25;13(1):4282. doi: 10.1038/s41467-022-31993-y. PMID: 35879315; PMCID: PMC9310361.

11. Li S, Hu Y, Li A, Lin J, Hsieh K, Schneiderman Z, Zhang P, Zhu Y, Qiu C, Kokkoli E, Wang TH, Mao HQ. Payload distribution and capacity of mRNA lipid nanoparticles. Nat Commun. 2022 Sep 23;13(1):5561. doi: 10.1038/s41467-022-33157-4. PMID: 36151112; PMCID: PMC9508184.

12. Wang X, Liu S, Sun Y, Yu X, Lee SM, Cheng Q, Wei T, Gong J, Robinson J, Zhang D, Lian X, Basak P, Siegwart DJ. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc. 2022 Oct 31. doi: 10.1038/s41596-022-00755-x. Epub ahead of print. PMID: 36316378.

13. Xue Y, Zhang Y, Zhong Y, Du S, Hou X, Li W, Li H, Wang S, Wang C, Yan J, Kang DD, Deng B, McComb DW, Irvine DJ, Weiss R, Dong Y. LNP-RNA-engineered adipose stem cells for accelerated diabetic wound healing. Nat Commun. 2024 Jan 25;15(1):739. doi: 10.1038/s41467-024-45094-5. PMID: 38272900; PMCID: PMC10811230.

14. Zhang W, Pfeifle A, Lansdell C, Frahm G, Cecillon J, Tamming L, Gravel C, Gao J, Thulasi Raman SN, Wang L, Sauve S, Rosu-Myles M, Li X, Johnston MJW. The Expression Kinetics and Immunogenicity of Lipid Nanoparticles Delivering Plasmid DNA and mRNA in Mice. Vaccines (Basel). 2023 Oct 11;11(10):1580. doi: 10.3390/vaccines11101580. PMID: 37896985; PMCID: PMC10610642.

15. Zhu Y, Ma J, Shen R, Lin J, Li S, Lu X, Stelzel JL, Kong J, Cheng L, Vuong I, Yao ZC, Wei C, Korinetz NM, Toh WH, Choy J, Reynolds RA, Shears MJ, Cho WJ, Livingston NK, Howard GP, Hu Y, Tzeng SY, Zack DJ, Green JJ, Zheng L, Doloff JC, Schneck JP, Reddy SK, Murphy SC, Mao HQ. Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity. Nat Biomed Eng. 2024 May;8(5):544-560. doi: 10.1038/s41551-023-01131-0. Epub 2023 Dec 11. PMID: 38082180; PMCID: PMC11162325.

16. Zhu Y, Cai SS, Ma J, Cheng L, Wei C, Aggarwal A, Toh WH, Shin C, Shen R, Kong J, Mao SA, Lao YH, Leong KW, Mao HQ. Optimization of lipid nanoparticles for gene editing of the liver via intraduodenal delivery. Biomaterials. 2024 Jul;308:122559. doi: 10.1016/j.biomaterials.2024.122559. Epub 2024 Apr 4. PMID: 38583366; PMCID: PMC11099935.

17. Jalil S, Keskinen T, Juutila J, Sartori Maldonado R, Euro L, Suomalainen A, Lapatto R, Kuuluvainen E, Hietakangas V, Otonkoski T, Hyvönen ME, Wartiovaara K. Genetic and functional correction of argininosuccinate lyase deficiency using CRISPR adenine base editors. Am J Hum Genet. 2024 Apr 4;111(4):714-728. doi: 10.1016/j.ajhg.2024.03.004. PMID: 38579669; PMCID: PMC11023919.

18. Yin X, Harmancey R, Frierson B, Wu JG, Moody MR, McPherson DD, Huang SL. Efficient Gene Editing for Heart Disease via ELIP-Based CRISPR Delivery System. Pharmaceutics. 2024 Feb 29;16(3):343. doi: 10.3390/pharmaceutics16030343. PMID: 38543237; PMCID: PMC10974117.

19. S Jalil - helda.helsinki.fi. Advancing Genetic Therapies: Developing Precision CRISPR Editing for Rare

20. Gao K, Han H, Cranick MG, Zhao S, Xu S, Yin B, Song H, Hu Y, Clarke MT, Wang D, Wong JM, Zhao Z, Burgstone BW, Farmer DL, Murthy N, Wang A. Widespread Gene Editing in the Brain via In Utero Delivery of mRNA Using Acid-Degradable Lipid Nanoparticles. ACS Nano. 2024 Nov 5;18(44):30293-30306. doi: 10.1021/acsnano.4c05169. Epub 2024 Oct 24. PMID: 39445691; PMCID: PMC11544762.

21. Li S, Hu Y, Lin J, Schneiderman Z, Shao F, Wei L, Li A, Hsieh K, Kokkoli E, Curk T, Mao HQ, Wang TH. Single-Particle Spectroscopic Chromatography Reveals Heterogeneous RNA Loading and Size Correlations in Lipid Nanoparticles. ACS Nano. 2024 Jun 18;18(24):15729-15743. doi: 10.1021/acsnano.4c02341. Epub 2024 Jun 5. PMID: 38839059; PMCID: PMC11191693.

22. Sanchez AJDS, Loughrey D, Echeverri ES, Huayamares SG, Radmand A, Paunovska K, Hatit M, Tiegreen KE, Santangelo PJ, Dahlman JE. Substituting Poly(ethylene glycol) Lipids with Poly(2-ethyl-2-oxazoline) Lipids Improves Lipid Nanoparticle Repeat Dosing. Adv Healthc Mater. 2024 Jul;13(17):e2304033. doi: 10.1002/adhm.202304033. Epub 2024 Mar 10. PMID: 38318754.

23. Cheng L, Zhu Y, Ma J, Aggarwal A, Toh WH, Shin C, Sangpachatanaruk W, Weng G, Kumar R, Mao HQ. Machine Learning Elucidates Design Features of Plasmid Deoxyribonucleic Acid Lipid Nanoparticles for Cell Type-Preferential Transfection. ACS Nano. 2024 Oct 22;18(42):28735-28747. doi: 10.1021/acsnano.4c07615. Epub 2024 Oct 7. PMID: 39375194; PMCID: PMC11512640.

24. Im SH, Chung Y, Duskunovic N, Choi H, Park SH, Chung HJ. Oligonucleotide-Linked Lipid Nanoparticles as a Versatile mRNA Nanovaccine Platform. Adv Healthc Mater. 2024 Oct 3:e2401868. doi: 10.1002/adhm.202401868. Epub ahead of print. PMID: 39363681.

25. Fazel F, Matsuyama-Kato A, Alizadeh M, Zheng J, Fletcher C, Gupta B, St-Denis M, Boodhoo N, Sharif S. A Marek's Disease Virus Messenger RNA-Based Vaccine Modulates Local and Systemic Immune Responses in Chickens. Viruses. 2024 Jul 18;16(7):1156. doi: 10.3390/v16071156. PMID: 39066318; PMCID: PMC11281610.

26. Luo J, Molbay M, Chen Y, Horvath I, Kadletz K, Kick B, Zhao S, Al-Maskari R, Singh I, Ali M, Bhatia HS, Minde DP, Negwer M, Hoeher L, Calandra GM, Groschup B, Su J, Kimna C, Rong Z, Galensowske N, Todorov MI, Jeridi D, Ohn TL, Roth S, Simats A, Singh V, Khalin I, Pan C, Arús BA, Bruns OT, Zeidler R, Liesz A, Protzer U, Plesnila N, Ussar S, Hellal F, Paetzold J, Elsner M, Dietz H, Erturk A. Nanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning. Nat Biotechnol. 2025 Jan 14. doi: 10.1038/s41587-024-02528-1. Epub ahead of print. PMID: 39809933.

27. Rahhal N, Rentzsch M, Seiser S, Freystätter C, Elbe-Bürger A, Rademacher C. Targeted delivery of cytotoxic proteins via lipid-based nanoparticles to primary Langerhans cells. Nanoscale. 2025 Jan 7. doi: 10.1039/d4nr03638g. Epub ahead of print. PMID: 39775685.

28. Torkzaban, Bahareh et al. Use of poly adenosine tail mimetics to enhance mRNA expression from genes associated with haploinsufficiency disorders. Molecular Therapy Nucleic Acids, Volume 0, Issue 0, 102453

29. Hong L, Ye T, Wang TZ, Srijay D, Liu H, Zhao L, Watson R, Vincoff S, Chen T, Kholina K, Goel S, DeLisa MP, Chatterjee P. Programmable protein stabilization with language model-derived peptide guides. Nat Commun. 2025 Apr 15;16(1):3555. doi: 10.1038/s41467-025-58872-6. PMID: 40229275; PMCID: PMC11997201.

30: Chung JY, Hong YK, Jeon E, Yang S, Park A, Weissleder R, Chong YP, Chung HJ. Effective treatment of systemic candidiasis by synergistic targeting of cell wall synthesis. Nat Commun. 2025 Jul 1;16(1):5532. doi: 10.1038/s41467-025-60684-7. PMID: 40595501; PMCID: PMC12215473.

31. Zhu Y, Yao ZC, Li S, Ma J, Wei C, Yu D, Stelzel JL, Ni BYX, Miao Y, Van Batavia K, Lu X, Lin J, Dai Y, Kong J, Shen R, Goodier KD, Liu X, Cheng L, Vuong I, Howard GP, Livingston NK, Choy J, Schneck JP, Doloff JC, Reddy SK, Hickey JW, Mao HQ. An mRNA lipid nanoparticle-incorporated nanofiber-hydrogel composite for cancer immunotherapy. Nat Commun. 2025 Jul 1;16(1):5707. doi: 10.1038/s41467-025-61299-8. PMID: 40592930; PMCID: PMC12217393.